Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is exhibiting promising outcomes in preliminary patient assessments . https://gogogobookmarks.com/story21386042/retatrutide-emerging-studies-and-potential-clinical-applications